MedTrace Logo

Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease

NCT00534651 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2019-12-03

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of orally given paracetamol on the vascular function and on 24-hour blood pressure in patients with coronary artery disease

Conditions

  • Coronary Arteriosclerosis
  • Endothelial Function

Interventions

DRUG

Paracetamol

Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Frank Ruschitzka, MD · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00534651 on ClinicalTrials.gov